QualityStocksNewsBreaks Archives - Page 852 of 1460

ThursdayDec 10, 2020 10:39 am

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176. The patent relates to VistaGen's PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in a variety of neuropsychiatric indications involving depression; the patent will not expire earlier than 2034. VistaGen is…

ThursdayDec 10, 2020 10:07 am

QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Lays Groundwork for Move into World of Psychedelics

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, today announced its engagement of a globally recognized operations, compliance and regulatory consulting firm to advise on the company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (“CDSA”). “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible,” said Pure Extracts…

ThursdayDec 10, 2020 9:47 am

QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate PCSA with a Speculative Buy rating as we consider the two leading assets in PCSA’s pipeline portfolio as most promising and with potential value. Eniluracil probably can reduce adverse events and improve efficacy of 5-FU/capecitabine…

WednesdayDec 09, 2020 2:49 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) on Track to Launch BaroShear K45 Nanoemulsification System in 2021

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative solutions for the worldwide life science and other industries, recently reported its third-quarter financial results and provided a business update, which included initial expectations for 2021 (https://ibn.fm/8PNFi). Among the updates, the Q3 2020 Form 10-Q financial report outlines measurable progress in three important areas: key operational and technical projects; revenue increases in the company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. A recent article discussing this reads, “Providing other updates and plans for 2021, the Form 10-Q report also mentioned that Pressure…

WednesdayDec 09, 2020 2:37 pm

QualityStocksNewsBreaks – Why Innovative Payment Solutions Inc. (IPSI) Is ‘One to Watch’

Innovative Payment Solutions (OTCQB: IPSI) is a digital payment technology service company that provides cutting-edge solutions for consumers and service providers. Leveraging its proprietary fintech payment architecture, the company is focused on building a 21st century payment platform. IPSI has spent the last five years perfecting its payment platform through its Mexico-based operations, which facilitate over two million users. A recent article discussing the company reads, “IPSI’s new business structure will use the latest technology, including blockchain and an e-wallet, to provide consumers the ability to make payments worldwide. The company’s innovative ecosystem will include multiple devices, such as POS…

WednesdayDec 09, 2020 1:40 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per…

WednesdayDec 09, 2020 1:18 pm

QualityStocksNewsBreaks – Tongji Healthcare Group Inc. (TONJ) Announces Plans to Acquire Disruptive Platform for Influencer-Based Marketing Strategies

Tongji Healthcare Group (OTC:TONJ) has signed a definitive agreement outlining the acquisition of Magiclytics, one of the world’s first influencer-based marketing revenue prediction software platforms. Using advanced analytics, machine learning and artificial intelligence (“AI”), the Magiclytics platform allows brands to identify the influencers they want to work with; the platform also offers guidance on revenue generation potential through influencer campaigns. TONJ expects this move to help current brand deals become more scalable and efficient, and provide an additional source of revenue. Over the past two years, Magiclytics has quietly gathered millions of data points from dozens of companies, experiencing success…

WednesdayDec 09, 2020 1:00 pm

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Participate at LD Micro Main Event

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Dr. Jack Regan, LexaGene’s CEO and founder, will present at the 13th Annual LD Micro Main Event Conference. Interested parties should visit https://ibn.fm/tKpNj to register for the event, slated to be held on Dec. 15, 2020. In addition, the company announced that it has engaged Native Ads Inc. of New York to perform strategic digital media, marketing and data analytics services including, but not limited to, content development, video production and editing, website development, media buying and distribution, and campaign…

WednesdayDec 09, 2020 12:26 pm

QualityStocksNewsBreaks – ISW Holdings Inc. (ISWH) Announces Agreement with Noteholders to Reduce Debt

ISW Holdings (OTC: ISWH), a global brand management holdings company, has reached an agreement with its largest noteholders to exchange approximately 50% of its current convertible debt for restricted preferred equity. The agreement eliminates a significant portion of the dilution potential from convertible debentures currently carried by ISW Holdings. The agreement calls for ISWH and its largest noteholder to exchange principal and interest with an aggregate value of $602K for restricted Preferred B equity. The move reduces total debt for ISWH and curtails dilution potential over the coming months and years. The agreement forms the basic template ISW Holdings intends…

WednesdayDec 09, 2020 11:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in…

Site Search

Company Search

Category: QualityStocksNewsBreaks